A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression.
Toll-like receptors (TLRs) function as primary sensors that elicit coordinated innate immune defenses through recognition of microbial products and induction of immune and proinflammatory genes. Here we report the identification and biological characterization of a lipopolysaccharide (LPS)-like molecule extracted from the cyanobacterium Oscillatoria Planktothrix FP1 (cyanobacterial product [CyP]) that is not stimulatory per se but acts as a potent and selective antagonist of bacterial LPS. CyP binds to MD-2 and efficiently competes with LPS for binding to the TLR4-MD-2 receptor complex. The addition of CyP together with LPS completely inhibited both MyD88- and TRIF-dependent pathways and suppressed the whole LPS-induced gene transcription program in human dendritic cells (DCs). CyP protected mice from endotoxin shock in spite of a lower capacity to inhibit LPS stimulation of mouse DCs. Interestingly, the delayed addition of CyP to DCs responding to LPS strongly inhibited signaling and cytokine production by immediate down-regulation of inflammatory cytokine mRNAs while not affecting other aspects of DC maturation, such as expression of major histocompatibility complex molecules, costimulatory molecules, and CCR7. Collectively, these results indicate that CyP is a potent competitive inhibitor of LPS in vitro and in vivo and reveal the requirement of sustained TLR4 stimulation for induction of cytokine genes in human DCs.
Macagno
Annalisa
A
Institute for Research in Biomedicine, CH-6500 Bellinzona, Switzerland. annalisa.macagno@irb.unisi.ch
Molteni
Monica
M
Rinaldi
Andrea
A
Bertoni
Francesco
F
Lanzavecchia
Antonio
A
Rossetti
Carlo
C
Sallusto
Federica
F
D000818:Animals; D000458:Cyanobacteria / Q000276:immunology*; D016207:Cytokines / Q000235:genetics*; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D008070:Lipopolysaccharides / Q000037:antagonists & inhibitors* / Q000494:pharmacology*; D051379:Mice; D012772:Shock, Septic / Q000517:prevention & control*; D051197:Toll-Like Receptor 4 / Q000276:immunology*; D014158:Transcription, Genetic / Q000187:drug effects
D016207:Cytokines; D008070:Lipopolysaccharides; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4